The Dubai Health Authority has granted preliminary approval to Yas Healthcare, a subsidiary of Das Holding, to establish the first proton therapy center in the United Arab Emirates.

This initiative aims to provide specialized treatments for cancer patients in Dubai, reflecting the strategic direction of Dubai in developing advanced healthcare services, and reinforcing its position as a key destination for specialized healthcare and medical tourism.

Construction of the center is expected to commence in the first quarter of 2026, with operations projected to begin by the end of 2028.

Proton therapy represents one of the most advanced radiation treatment technologies available worldwide, allowing for the delivery of precise radiation doses to malignant tumors while minimizing damage to surrounding healthy tissues.

This makes it particularly suitable for sensitive cases such as pediatric tumors and complex cancers.

The new center is anticipated to enable patients to receive this treatment within the UAE, reducing costs and alleviating the psychological burden on patients and their families from traveling abroad for care.

Dr. Alawi Sheikh Ali, Director-General of the Dubai Health Authority, emphasized that the project embodies the vision of His Highness Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, for establishing a comprehensive healthcare system anchored in innovation and prioritizing patient care.

It aligns with the directives of His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and Chairman of the Executive Council, to accelerate the adoption of future solutions and enhance quality partnerships that improve healthcare standards and contribute to better quality of life.

Dr. Alawi further noted that the new center will contribute to providing advanced patient-centered treatment services, improving access to precise care, and supporting Dubai's ambition to be among the top 10 cities worldwide in terms of healthy life expectancy.

This effort is in line with the National Strategy for Quality of Life 2031 and Dubai's Social Agenda 33 and Economic Agenda D33.

The project is being developed in collaboration with the National Cancer Centre in Singapore (NCCS), a prominent medical institution specializing in cancer treatment in Asia, which will serve as the technical advisor for the project, providing clinical and technical expertise, and applying global standards in the design and operation of the facility.

Dr. Mohammed Zaki, Chief Medical Officer and Director General of Yas Healthcare, stated that global data indicates an increasing incidence of cancer, particularly among younger age groups.

He highlighted that proton therapy is a less toxic and more precise treatment option for such cases, aiming to reduce reliance on overseas treatment and deliver high-quality medical services in Dubai.

Dr. Michael Wang, Head of Radiation Oncology at the National Cancer Centre in Singapore, expressed pride in participating in the project and underscored that the collaboration with Yas Healthcare represents an extension of the NCCS's role in leading advancements in radiation treatment technologies, indicating that the center will be a significant step in reshaping the cancer treatment experience in the Gulf region.

Yas Healthcare, part of Das Holding in the UAE, is committed to providing innovative patient-centered solutions and focuses on addressing gaps in specialty care through strategic partnerships and advanced technologies.

The National Cancer Centre in Singapore is a leading national and regional institution in oncology, offering comprehensive multidisciplinary care and access to innovative treatments, including proton therapy, while aiming to be a globally recognized center of excellence in cancer treatment.